MAPS Responds to FDA Continue Clinical Hold Letter from FDA Regarding Expanded Access Protocol with Protocol A2V1

In June 2019, MAPS responded to the U.S. Food and Drug Administration’s (FDA) continue clinical hold letter regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) with Protocol A2V1.